Cannara Biotech Inc. (V:LOVE)
Business Focus: Medical Farming
| Sector: Healthcare | Industry: Healthcare Facilities & Services |
| Company Contact | |
| Address: | Suite 2050 - 1055, West Georgia Street VANCOUVER BC V6E 3P3 |
| Tel: | 1-514-5434200 |
| Website: | https://www.cannara.ca/en |
| IR: | See website |
| Key People | ||
| Zohar Krivorot Chairman of the Board, Chief Executive Officer | Nicholas Sosiak Chief Financial Officer | Avi Krivorot Chief Technology Officer |
| Noemi Follain Vice President - Finance | Anthony Manouk Vice President - Compliance, General Manager | |
| Business Overview |
| Cannara Biotech Inc. is a Canada-based vertically integrated producer of premium-grade cannabis and cannabis-derivative products for the Quebec and Canadian markets. It operates through its wholly owned subsidiaries, Cannara Biotech (Quebec) Inc. and Cannara Biotech (Valleyfield) Inc. The Company owns two mega facilities based in Quebec spanning over 1,650,000 square feet, providing the Company with 100,000 kilograms of annualized cultivation output. It operates in two segments: Cannabis operations and Real estate operations. The Cannabis operations, which encompasses the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and other cannabis services (Cannabis operations). The Real estate operations, related to the Farnham and Valleyfield building (Real estate operations). The Company's brand portfolio includes Tribal, Nugz, and Orchid CBD. Orchid CBD is a wellness brand that provides premium CBD-dominant cannabis. |
| Financial Overview |
| For the three months ended 30 November 2023, Cannara Biotech Inc revenues increased 89% to C$19.5M. Net income increased from C$3K to C$2.1M. Revenues reflect Cannabis operations segment increase of 97% to C$18.6M, Real estate operations segment increase of 5% to C$909K. Net income benefited from Cannabis operations segment income increase from C$1.2M to C$3.3M, Real estate operations segment income increase of 7% to C$837K. |
| Reporting Currency: | Canadian Dollars |
| Enterprise value: | $117.34M as of Nov 30, 2023 |
| Annual revenue (TTM): | $66.73M as of Nov 30, 2023 |
| EBITDA (TTM): | -$5.13M as of Nov 30, 2023 |
| Net annual income (TTM): | $9.05M as of Nov 30, 2023 |
| Free cash flow (TTM): | -$2.28M as of Nov 30, 2023 |
| Net Debt Last Fiscal Year: | $46.02M as of Nov 30, 2023 |
| Shares outstanding: | 90,018,952 as of Dec 12, 2023 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
